A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Diffuse, Large B-Cell, Lymphoma Clinical Trial

Official title:
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Status Terminated

Clinical Trial Summary

A study to evaluate the Efficacy and Safety of Polatuzumab Vedotin in combination with BR (Bendamustine and Rituximab) compared with BR alone in Chinese participants with R/R DLBCL. Approximately 42 Chinese participants will be randomised to treatment arms in a 2:1 ratio. Randomisation will be conducted with the aid of an interactive web-based response system (IxRS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04236141
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Terminated
Phase	Phase 3
Start date	July 10, 2020
Completion date	February 7, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02871869` - Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma	Phase 2/Phase 3
Completed	`NCT01848132` - Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.	Phase 2
Terminated	`NCT02374424` - Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients	Phase 2
Completed	`NCT02391116` - Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Phase 2
Completed	`NCT00599170` - Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	Phase 2
Completed	`NCT02867566` - A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients	Phase 3
Terminated	`NCT02855359` - Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma	Phase 2
Completed	`NCT02216890` - Safety Study of SGN-CD70A in Cancer Patients	Phase 1
Active, not recruiting	`NCT01181271` - Tandem Auto-Allo Transplant for Lymphoma	Phase 2